IBS Inc.

Future Tests

One Platform, Multiple Diagnostic Tests

Diagnostic Tests

The Biosensor Platform uses Organic Thin Film Transistor (OTFT) technology, which can be printed at scale and low cost. By substituting the detection element (region A), depending on the analyte to be detected, the Biosensor has the potential to be modified to monitor a wide range of saliva-based diagnostic analytes, ranging from glucose to immunological conditions and communicable diseases. The Biosensor Platform has the potential to test for up to 130 indications.

We are currently developing two urgently needed innovations using the Biosensor Platform: SARS-CoV-2 and glucose.

Future Tests Pipeline


The pilot diagnostic test is SARS-CoV-2, and the portfolio will consist of various communicable disease tests including hepatitis A, B & C, HIV and TORCH.

The pilot diagnostic test is saliva glucose. The diagnostic test portfolio includes other clinical chemistry tests (e.g., cholesterol).